ADVFN - Advanced Financial Network.
HOME» NASDAQ » M » MYL Stock Price » MYL Stock News

Mylan Inc. Share News

 Mylan Inc. (mm) Stock Price
MYL Stock Price
 Mylan Inc. (mm) Stock Chart
MYL Stock Chart
 Mylan Inc. (mm) Stock News
MYL Stock News
 Mylan Inc. (mm) Company Information
MYL Company Information
 Mylan Inc. (mm) Stock Trades
MYL Stock Trades

Mylan Confirms Endo Suit Over Generic Migraine Drug Application

DOW JONES NEWSWIRES Mylan Inc. (MYL) confirmed Wednesday that it has been sued by Endo Pharmaceuticals Holdings Inc. (ENDP) over its application for approval of a generic drug used to treat acute migraine headaches in adults. Mylan--one of the world's largest generic drug makers--said it believes it is the first company to file a substantially complete application for approval of frovatriptan succinate EQ, a generic version of Frova. The company said it expects to qualify for 180 days of marketing exclusivity upon final approval from the Food and Drug Administration. Mylan, which has had litigation-related charges figure prominently in its recent quarterly results, last month reported second-quarter earnings surged 70% as sales got a lift from a weaker dollar. Shares closed Tuesday at $20.01 and were inactive in recent premarket trade. Through the latest close, the stock is down 5.3% since the start of the year. -By Mia Lamar, Dow Jones Newswires; 212-416-3207; mia.lamar@dowjones.com

Stock News for Mylan Inc. (MYL)
DateTimeHeadline
07/21/201617:17:10Filing of Certain Prospectuses and Communications in Connection...
07/21/201613:00:00Mylan Publishes Supplement to Meda Offer Document
07/21/201613:00:00Mylan Publishes Supplement to Meda Offer Document
07/21/201610:00:00Mylan and Biocon Announce Regulatory Submission for Proposed...
07/20/201612:20:00EU Approves Mylan's $7.2 Billion Acquisition of Meda
07/20/201611:03:00Mylan Launches Generic Crestor® Tablets
07/20/201609:20:00Abbott Labs Profit Tops Views
07/15/201607:30:00Market Updates on Drugs - Generic Equities -- Mylan, Horizon...
07/11/201607:30:00Mylan Launches Generic Temodar® Capsules
07/07/201610:47:00Mylan to Report Second Quarter 2016 Financial Results on August...
07/06/201607:30:00Mylan Launches Generic Fenoglide® Tablets
06/24/201619:01:25Statement of Changes in Beneficial Ownership (4)
06/24/201617:12:44Filing of Certain Prospectuses and Communications in Connection...
06/24/201617:02:20Current Report Filing (8-k)
06/24/201611:44:00Mylan Launches Generic Avodart® Capsules
06/23/201611:22:00Mylan Donates €1 Million to the Princess Máxima Center for Pe...
06/20/201617:17:23Filing of Certain Prospectuses and Communications in Connection...
06/20/201609:54:00Attorney General Rejects VEB's Request Regarding Mylan Shareholder...
06/17/201608:00:00Drugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon...
06/17/201606:01:39Notice of Effectiveness (effect)

Mylan Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad